Shanghai fine-chemistry CO., Ltd 86-21-17617767348-1
154229-18-2 Abiraterone Acetate Anti Cancer Immunity C26H33NO2 620-314-7

154229-18-2 Abiraterone Acetate Anti Cancer Immunity C26H33NO2 620-314-7

  • High Light

    154229-18-2 Pharmaceutical Intermediates


    Abiraterone Acetate


    Anti Cancer Abiraterone Acetate

  • Product Name
    Abiraterone Acetate
  • Synonyms
    [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] Acetate;(3β)-17-(3-pyridinyl) Androsta-5,16-dien-3-yl Acetate;Abiraterone Acetate, >=99%;Abirteroneacetate;ZYTIGA
  • CAS
  • MF
  • MW
  • Melting Point
  • Boiling Point
    506.7±50.0 °C(Predicted)
  • Density
    1.14±0.1 G/cm3(Predicted)
  • Storage Temp
    -20°C Freezer
  • Purity
  • Place of Origin
  • Brand Name
  • Certification
  • Model Number
  • Minimum Order Quantity
  • Price
  • Packaging Details
    10g 50g 100g 500g 1kg
  • Delivery Time
    3-7 days
  • Payment Terms
    T/T, MoneyGram, BTCcoin
  • Supply Ability
    1kg --100kg

154229-18-2 Abiraterone Acetate Anti Cancer Immunity C26H33NO2 620-314-7

SECTION 1: Basic information

Abiraterone acetate Basic information
Product Name: Abiraterone acetate
Synonyms: Abiraterone Acotate;Abiraterone Acetate impurity;(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate;[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate;(3β)-17-(3-pyridinyl) androsta-5,16-dien-3-yl acetate;Abiraterone acetate, >=99%;Abirteroneacetate;ZYTIGA
CAS: 154229-18-2
MF: C26H33NO2
MW: 391.55
EINECS: 620-314-7
Product Categories: Inhibitors;Inhibitor;API;DQM;Final material;Anti-cancer & immunity;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
Mol File: 154229-18-2.mol
Abiraterone acetate Structure
Abiraterone acetate Chemical Properties
Melting point 127-130°C
Boiling point 506.7±50.0 °C(Predicted)
density 1.14±0.1 g/cm3(Predicted)
storage temp. -20°C Freezer
pka 5.31±0.12(Predicted)
form powder
color white to beige
Safety Information
WGK Germany 3
RTECS BV7992100
Abiraterone acetate Usage And Synthesis
Description In April 2011, the United States FDA approved abiraterone acetate (CB7630) in combination with the steroid prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for patients who were previously treated with a docetaxel containing regimen for late-stage disease. Abiraterone acetate affects prostate, testicular, and adrenal androgens by irreversibly inhibiting both the lyase and hydroxylase activity of cytochrome P450 17A (CYP17) signaling pathways (IC50's of 2.9 and 4 nM, respectively) thereby decreasing testosterone levels.Most common serious adverse events for abiraterone acetate versus placebo included fluid retention (30.5% vs. 22.3%), hypokalemia (17.1% vs. 8.4%), hypertension (9.7% vs. 7.9%), hepatic transaminase abnormalities (10.4% vs. 8.1%), and cardiac abnormalities (13.3% vs. 10.4%).
Chemical Properties Off-White Solid
Originator Institute of Cancer Research, London (United Kingdom)
Uses Abiraterone acetate is a novel steroidal inhibitor of human Cytochrome P450 (17α-Hydroxylase-C17,20-lyase): potential agent for the treatment of prostatic cancer.
Uses Abiraterone acetate was approved by the U.S. Food and Drug Administration (FDA) in April 2011 for the treatment of castrationresistant prostate cancer. The drug, marketed under the trade name Zytiga, was originally discovered by researchers at the Cancer Research UK Centre for Cancer Therapeutics in 1990, developed by Cougar Biotechnology, and ultimately commercialized by Johnson & Johnson after its acquisition of Cougar in 2009. Abiraterone acetate inhibits CYP17A1—an enzyme expressed in testicular, adrenal, and prostatic tumor tissues—which has been implied in the production of testosterone and the proliferation of such tumor cell lines.

SECTION 2: Hazard identification

2.1 Classification of the substance or mixture

Acute toxicity - Category 4, Oral

Reproductive toxicity, Category 2

2.2 GHS label elements, including precautionary statements

Pictogram(s) 154229-18-2 Abiraterone Acetate Anti Cancer Immunity C26H33NO2 620-314-7 1 154229-18-2 Abiraterone Acetate Anti Cancer Immunity C26H33NO2 620-314-7 2
Signal word Warning
Hazard statement(s)

H302 Harmful if swallowed

H361 Suspected of damaging fertility or the unborn child

Precautionary statement(s)

P264 Wash ... thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P203 Obtain, read and follow all safety instructions before use.

P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...


P301+P317 IF SWALLOWED: Get medical help.

P330 Rinse mouth.

P318 IF exposed or concerned, get medical advice.

Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

2.3 Other hazards which do not result in classification

no data available

SECTION 3: Composition/information on ingredients

3.1 Substances

Chemical name Common names and synonyms CAS number EC number Concentration
(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate(3beta)-17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-yl acetate17-(3-pyridyl)-5,16-androstadien-3 beta acetateAbiraterone AcetateAndrosta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3b)-Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)-[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate(3beta)-17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-yl acetate17-(3-pyridyl)-5,16-androstadien-3 beta acetateAbiraterone AcetateAndrosta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3b)-Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)-[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate 154229-18-2 - 100%

SECTION 4: First-aid measures

4.1 Description of necessary first-aid measures

If inhaled

Move the victim into fresh air. If breathing is difficult, give oxygen. If not breathing, give artificial respiration and consult a doctor immediately. Do not use mouth to mouth resuscitation if the victim ingested or inhaled the chemical.

Following skin contact

Take off contaminated clothing immediately. Wash off with soap and plenty of water. Consult a doctor.

Following eye contact

Rinse with pure water for at least 15 minutes. Consult a doctor.

Following ingestion

Rinse mouth with water. Do not induce vomiting. Never give anything by mouth to an unconscious person. Call a doctor or Poison Control Center immediately.

4.2 Most important symptoms/effects, acute and delayed

no data available

4.3 Indication of immediate medical attention and special treatment needed, if necessary

no data available

SECTION 5: Fire-fighting measures

5.1 Suitable extinguishing media

Use dry chemical, carbon dioxide or alcohol-resistant foam.

5.2 Specific hazards arising from the chemical

no data available

5.3 Special protective actions for fire-fighters

Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Avoid dust formation. Avoid breathing mist, gas or vapours.Avoid contacting with skin and eye. Use personal protective equipment.Wear chemical impermeable gloves. Ensure adequate ventilation.Remove all sources of ignition. Evacuate personnel to safe areas.Keep people away from and upwind of spill/leak.

6.2 Environmental precautions

Prevent further spillage or leakage if it is safe to do so. Do not let the chemical enter drains. Discharge into the environment must be avoided.

6.3 Methods and materials for containment and cleaning up

Collect and arrange disposal. Keep the chemical in suitable and closed containers for disposal. Remove all sources of ignition. Use spark-proof tools and explosion-proof equipment. Adhered or collected material should be promptly disposed of, in accordance with appropriate laws and regulations.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

7.2 Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure limit values

no data available

Biological limit values

no data available

8.2 Appropriate engineering controls

Ensure adequate ventilation. Handle in accordance with good industrial hygiene and safety practice. Set up emergency exits and the risk-elimination area.

8.3 Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection

Wear tightly fitting safety goggles with side-shields conforming to EN 166(EU) or NIOSH (US).

Skin protection

Wear fire/flame resistant and impervious clothing. Handle with gloves. Gloves must be inspected prior to use. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.

Respiratory protection

If the exposure limits are exceeded, irritation or other symptoms are experienced, use a full-face respirator.

Thermal hazards

no data available